Clinical Trial News and Research

RSS

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

Silence Therapeutics plc, a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc., has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.

20 Aug 2010

Bioniche provides update on Urocidin clinical development program for non-muscle-invasive bladder cancer

Bioniche Life Sciences Inc., a research-based, technology driven Canadian biopharmaceutical company, today provided an update on the clinical development program for its proprietary product for non-muscle-invasive bladder cancer - Urocidin.

20 Aug 2010

Trius Therapeutics second quarter 2010 revenue increases to $2.1 million

Trius Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections, announced today its financial results for the three months ended June 30, 2010.

20 Aug 2010

Neovasc revenue increases 60% for second quarter 2010

Neovasc Inc., today announced financial results for the three and six months ended June 30, 2010. "In this most recent quarter Neovasc continued to demonstrate robust year-over-year revenue growth from sales of our biological tissue and consulting services businesses," said Alexei Marko, chief executive officer of Neovasc.

19 Aug 2010

PAREXEL International launches temperature recording solution optimized for clinical trial supply process

PAREXEL International Corporation, a leading global biopharmaceutical services organization, today announced that it has introduced an integrated temperature recording solution for study drug transportation as part of its expanded Clinical Logistics Services.

From Parexel 19 Aug 2010

Advaxis completes low dose group patient dosing in phase II cervical dysplasia clinical trial study

Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has completed the nine (9) doses to be administered to the three (3) vanguard patients in the low dose group of its phase II cervical dysplasia clinical trial study.

19 Aug 2010

Scientists reveal lab approach method to treat neuroblastoma in children

A study led by scientists at The Hospital for Sick Children (SickKids) reveals a new method of identifying drugs to treat children suffering from fatal cancers for which an effective treatment has not been found. Rather than developing a new drug from scratch, which is a complicated and time-consuming process, they tried a different approach: in the lab, they tested existing drugs on cancer stem cells from young patients with neuroblastoma, one of the common cancers of infants and children.

19 Aug 2010

Rush University Medical Center tests new drug therapy for West Nile fever

Neurological and infectious disease experts at Rush University Medical Center are testing a new drug therapy for the treatment of individuals with West Nile fever or suspected central nervous system infection due to the West Nile virus. Rush is the only site in the Midwest enrolling patients into the $50 million dollar, NIH-funded, Phase II clinical trial called PARADIGM.

18 Aug 2010

Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has locked the database of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON™ (OX1).

18 Aug 2010

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.

18 Aug 2010

AMT's MAA for LPLD gene therapy product Glybera on schedule

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that the Marketing Authorisation Application (MAA) for Glybera(R) remains on schedule following meetings with the European Medicine Agency (EMA) concerning the Day 120 List of Questions. The company is confident that Glybera(R), a gene therapy product for lipoprotein lipase deficiency (LPLD), remains on track for a regulatory decision by mid-2011.

18 Aug 2010

Lilly to halt development of potential Alzheimer's disease drug semagacestat

Eli Lilly and Company will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long-term Phase III studies showed it did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living.

18 Aug 2010

NACTN receives grant to expand spinal cord injury research

The United States Department of Defense (DoD) awarded the Christopher & Dana Reeve Foundation a $5.4 million grant to support the expansion of translational research to find treatments for military men and women with spinal cord injuries.

18 Aug 2010

Psychological support from health visitors prevents depression after child birth: Study

The world's first ever analysis of data from a full scale clinical trial in adults shows that training Health Visitors to assess and psychologically support mothers after childbirth can prevent the development of depression over the following year.But the substantial reduction in the number of NHS health visitors was identified by researchers as a key issue for the health and well-being of mums.

18 Aug 2010

NIH awards Brain Plasticity $3.65M to improve cognitive function in people with schizophrenia

Brain Plasticity Inc., a new technology incubator dedicated to the discovery and development of novel technologies that harness the basic principles of brain plasticity to improve the lives of people with neurological and psychiatric disorders, was recently awarded $3.65 million dollars in two separate grants from the National Institutes of Health (NIH).

18 Aug 2010

NCI grants SBIR award to MabVax Therapeutics

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP).

18 Aug 2010

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

ImmunoCellular Therapeutics today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations during the quarter. The increase in net burn is reflective of increased personnel costs as well as increase in Research and Development costs associated with the planned phase II clinical trial for ICT-107.

18 Aug 2010

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.

17 Aug 2010

Xenon Pharmaceuticals commences phase 2 clinical trial of XEN402 therapy for PHN

Xenon Pharmaceuticals Inc. announced today that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of PHN.

17 Aug 2010

European Cancer Cluster Meeting 2010 to be held September 15-17 in Oslo, Norway

Europe's most promising oncology biotechs and other key stakeholders will gather in Oslo, Norway, September 15-17 for the 2nd European Cancer Cluster Meeting (ECCP 2010). Co-hosted by the Oslo Cancer Cluster and the Cancer-Bio-Santé Cluster from Toulouse, the two-day meeting is a unique partnering opportunity for oncology biotech companies, business development and licensing executives from the pharmaceutical industry and investors, as well as innovative researchers and clinicians.

17 Aug 2010

Clinical Trial News and Research

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

Bioniche provides update on Urocidin clinical development program for non-muscle-invasive bladder cancer

Trius Therapeutics second quarter 2010 revenue increases to $2.1 million

Neovasc revenue increases 60% for second quarter 2010

PAREXEL International launches temperature recording solution optimized for clinical trial supply process

Advaxis completes low dose group patient dosing in phase II cervical dysplasia clinical trial study

Scientists reveal lab approach method to treat neuroblastoma in children

Rush University Medical Center tests new drug therapy for West Nile fever

Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

AMT's MAA for LPLD gene therapy product Glybera on schedule

Lilly to halt development of potential Alzheimer's disease drug semagacestat

NACTN receives grant to expand spinal cord injury research

Psychological support from health visitors prevents depression after child birth: Study

NIH awards Brain Plasticity $3.65M to improve cognitive function in people with schizophrenia

NCI grants SBIR award to MabVax Therapeutics

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Xenon Pharmaceuticals commences phase 2 clinical trial of XEN402 therapy for PHN

European Cancer Cluster Meeting 2010 to be held September 15-17 in Oslo, Norway

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News